New shot targets rare, aggressive blood cancer
NCT ID NCT07222579
Summary
This study is testing an immunotherapy drug called blinatumomab, given as an injection under the skin, for adults with a rare and aggressive type of blood cancer (CD19+ MPAL). It aims to see if the treatment can help patients live longer, achieve deep remissions with no detectable cancer, or control the disease if it has come back. The trial is for 78 adults in three groups: newly diagnosed patients who can't tolerate strong chemo, patients in remission but with tiny amounts of leftover cancer, and patients whose cancer has returned or resisted prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West Virginia University Cancer Institute
RECRUITINGMorgantown, West Virginia, 26506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.